Ketorolac Tromethamine Injection, Solution
Product Images NDC 51662-1669

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Ketorolac Tromethamine (NDC 51662-1669). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (0409 3796 25 Ketorolac Tromethamine Vial Image)

Label (0409 3796 25 Ketorolac Tromethamine Vial Image)
FDA Label Image

Table (51662 1669 Table 1)

Table (51662 1669 Table 1)
FDA Label Image

Table (51662 1669 Table 3)

Table (51662 1669 Table 3)
This text provides a list of gastrointestinal experiences and other potential side effects associated with a certain condition or medication. The gastrointestinal symptoms mentioned include abdominal pain, constipation, diarrhea, dyspepsia, flatulence, fullness, ulcers, gross bleeding, perforation, heartburn, nausea, stomatitis, and vomiting. Additionally, other experiences listed involve abnormal renal function, anemia, dizziness, drowsiness, eczema, elevated liver enzymes, headaches, hypertension, increased bleeding time, injection site pain, pruritus, purpura, rashes, tinnitus, and sweating. The overall incidence of these side effects is reported to be greater than 10%.*
FDA Label Image

Structure (51662 1669 Structure)

Structure (51662 1669 Structure)
This text describes a chemical reaction involving compounds with the formulas C15H13NO3 and C8H11NO2. It also includes a figure labeled as "FIGURE 1" with a chemical equation showing the conversion of one compound to another.*
FDA Label Image

Table (51662 1669 Table 2)

Table (51662 1669 Table 2)
FDA Label Image

Table (51662 1669 Table 4)

Table (51662 1669 Table 4)
This is a table displaying the incidence of clinically serious bleeding in relation to age, total daily dose, and history of gastrointestinal bleeding after up to 5 days of treatment with Ketorolac Tromethamine Injection. The data is divided into two sections: one for adult patients without a history of gastrointestinal issues and another for adult patients with a history of gastrointestinal bleeding. The table provides percentages of bleeding incidents based on different age groups and total daily doses of the medication.*
FDA Label Image

Label (51662 1669 1 Vial Label)

Label (51662 1669 1 Vial Label)
This text contains a series of identification numbers or codes, a mention of the manufacturer's insert, and information about the distributor HF Acquisition Co., LLC located in Mukilteo, WA 58275. It also mentions that the content is for prescription (Rx) use only.*
FDA Label Image

Label (51662 1669 2 Pouch Label)

Label (51662 1669 2 Pouch Label)
This text provides information on Ketorolac Tromethamine injection, USP in a 60mg/2mL vial. The medication is for intramuscular use only and each mL contains 30mg of Ketorolac Tromethamine, along with 10% alcohol and 4.35mg of sodium chloride. The pH is adjusted to 7.4 and the vial should be discarded after use. The expiration date is 2023-89-19 and the lot number is 789218. The manufacturer's original NDC is 0409-3796-25. Recommended dosage and other prescribing information can be found in the package insert. The product should be stored at controlled room temperature. Distributed by HF Acgursitien e, LEC in Mukilteo, WA 98275.*
FDA Label Image

Label (51662 1669 3 Box Label)

Label (51662 1669 3 Box Label)
This text is a detailed description of Ketorolac Tromethamine injection, USP. It provides information on the dosage strength, vial size, NDC number, lot number, and expiration date. Additionally, the text offers instructions for use, storage conditions, and the manufacturer's details. The medication is intended for intramuscular use only, with each mL containing 30mg of Ketorolac Tromethamine. Users are advised to discard any unused portions. The text also mentions the presence of alcohol, sodium chloride, and possible pH-adjusting agents in the solution. Overall, this description provides essential details for the proper use and handling of the Ketorolac Tromethamine injection.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.